Every year, Mintz provides analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission and their annual shareholder meetings. This memorandum discusses key considerations to keep in mind as you embark upon the year-end reporting process in 2025.
Although the SEC was not as active in adopting new rules in 2024 as the previous few years, this year public companies should continue to refine their disclosures and year-end process to address the SEC’s earlier rule making activities. In particular, companies need to be aware of the developing landscape of cybersecurity disclosures and the required disclosure of insider trading policies and option awards made close in time to the release of material non-public information. Additionally, companies need to assess the impact artificial intelligence may have on their business and review their AI disclosures carefully and continue to update their Environmental, Social, and Governance practices and disclosures.
In addition to summarizing these considerations, we address several other significant developments and considerations companies should focus on this year, including the need to thoughtfully review and refine risk factors and Management’s Discussion and Analysis of Financial Condition. We also provide an update on noteworthy U.S. Food and Drug Administration regulatory developments and recent litigation impacting corporate governance and disclosure.
{Read the full Advisory}
[View source.]
